CA2205134A1 - A method for treating vascular headaches - Google Patents

A method for treating vascular headaches

Info

Publication number
CA2205134A1
CA2205134A1 CA002205134A CA2205134A CA2205134A1 CA 2205134 A1 CA2205134 A1 CA 2205134A1 CA 002205134 A CA002205134 A CA 002205134A CA 2205134 A CA2205134 A CA 2205134A CA 2205134 A1 CA2205134 A1 CA 2205134A1
Authority
CA
Canada
Prior art keywords
treating vascular
vascular headaches
migraine headache
treating
headaches
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002205134A
Other languages
French (fr)
Other versions
CA2205134C (en
Inventor
Michael A. Moskowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
The General Hospital Corporation
Michael A. Moskowitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, Michael A. Moskowitz filed Critical The General Hospital Corporation
Publication of CA2205134A1 publication Critical patent/CA2205134A1/en
Application granted granted Critical
Publication of CA2205134C publication Critical patent/CA2205134C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Noodles (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for treating migraine headache.
The methods useful according to the invention involve the treatment of patients who experience symptoms of migraine headache with compounds that directly or indirectly activate GABA A receptors.
CA002205134A 1994-11-18 1995-11-17 A method for treating vascular headaches Expired - Fee Related CA2205134C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/342,090 US5767117A (en) 1994-11-18 1994-11-18 Method for treating vascular headaches
US08/342,090 1994-11-18
PCT/US1995/015070 WO1996015782A1 (en) 1994-11-18 1995-11-17 A method for treating vascular headaches

Publications (2)

Publication Number Publication Date
CA2205134A1 true CA2205134A1 (en) 1996-05-30
CA2205134C CA2205134C (en) 2008-08-19

Family

ID=23340286

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205134A Expired - Fee Related CA2205134C (en) 1994-11-18 1995-11-17 A method for treating vascular headaches

Country Status (10)

Country Link
US (2) US5767117A (en)
EP (2) EP1839657A3 (en)
JP (2) JPH10509178A (en)
AT (1) ATE362361T1 (en)
CA (1) CA2205134C (en)
DE (1) DE69535498T2 (en)
DK (1) DK0789567T3 (en)
ES (1) ES2289745T3 (en)
PT (1) PT789567E (en)
WO (1) WO1996015782A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6787530B1 (en) 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
CA2270531C (en) * 1996-11-05 2011-08-30 Head Explorer Aps A method for treating tension-type headache
WO2000037616A1 (en) * 1998-12-23 2000-06-29 Cytoscan Sciences L.L.C. Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
WO2000054588A1 (en) * 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
GB9906130D0 (en) * 1999-03-18 1999-05-12 Knoll Ag Compounds for use in therapy
DE60013811T2 (en) * 1999-05-04 2005-11-17 Keith R. Edwards INTRAVENOUS ADMINISTRATION OF VALPROAT FOR THE TREATMENT OF MIGRAINE HEADACHES
US6333345B1 (en) * 1999-05-14 2001-12-25 Sepracor, Inc. Methods of using and compositions comprising N-desmethylzolpidem
NZ515616A (en) 1999-07-06 2004-05-28 Lilly Co Eli Selective iGluR5 receptor antagonists for the treatment of migraine
AU2574801A (en) 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
WO2002053556A2 (en) * 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
US6953805B2 (en) * 2001-01-05 2005-10-11 Eli Lilly And Company Excitatory amino acid receptor antagonists
US7205313B2 (en) * 2001-01-05 2007-04-17 Eli Lilly And Company Excitatory amino acid receptor antagonists
US6924294B2 (en) * 2001-01-05 2005-08-02 Eli Lilly And Company Excitatory amino acid receptor antagonists
EP1392258B1 (en) * 2001-05-24 2008-11-26 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005503425A (en) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション Delivery of drug ester by the prescribed inhalation route
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
KR20040018434A (en) * 2001-07-09 2004-03-03 야마노우치세이야쿠 가부시키가이샤 Sustained-release compositions for injection and process for producing the same
US20030045541A1 (en) * 2001-07-23 2003-03-06 Christopher Bruckner GABA-Receptor modulators with NMDA-Antagonistic activity
SE0104423D0 (en) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
NZ535245A (en) 2002-04-26 2007-11-30 Lilly Co Eli Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgesics
US20050176068A1 (en) * 2002-04-26 2005-08-11 Emmert-Buck Michael R. Direct cell target analysis
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
WO2004066930A2 (en) * 2003-01-27 2004-08-12 Arthur Zaks Method for inducing pain relief using imidazo[1,2-a]pyridine derivatives
US20040241100A1 (en) * 2003-03-17 2004-12-02 Fabre Kramer Pharmaceutical, Inc. Nasally administrable compositions of zolpidem and methods of use
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
US7657309B2 (en) * 2003-05-28 2010-02-02 The Ohio State University Measuring human heart muscle viability using myocardial electrical impedance
US20050070524A1 (en) * 2003-06-06 2005-03-31 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
EP1836161B1 (en) * 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
PL1868614T3 (en) * 2005-03-24 2013-01-31 Univ Emory Dosage regimen for the treatment of a traumatic brain injury with progesterone
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
PT3851447T (en) 2006-10-12 2023-12-11 Bellus Health Inc Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
EP3056220A1 (en) * 2007-04-11 2016-08-17 John A. Mccarty Hormone tablet and metods of preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35517A (en) * 1862-06-10 Improved sofa, convertible into a table, trunk, cot
JPS6019713A (en) * 1983-07-13 1985-01-31 Yakurigaku Chuo Kenkyusho:Kk Remedy for angiocephalalgia and remedy for hangover containing gamma-aminobutyric acid or its derivative as main active ingredient
US5189064A (en) * 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
DK0808325T3 (en) * 1994-11-23 2001-01-29 Cocensys Inc Androstan and pregnancies for allosteric modulation of GABA receptor

Also Published As

Publication number Publication date
EP1839657A3 (en) 2007-12-19
DE69535498T2 (en) 2008-01-24
US5767117A (en) 1998-06-16
DE69535498D1 (en) 2007-06-28
ATE362361T1 (en) 2007-06-15
EP0789567A1 (en) 1997-08-20
EP0789567A4 (en) 1999-01-13
JP2007291143A (en) 2007-11-08
US5929061A (en) 1999-07-27
ES2289745T3 (en) 2008-02-01
JPH10509178A (en) 1998-09-08
CA2205134C (en) 2008-08-19
DK0789567T3 (en) 2007-09-24
EP0789567B1 (en) 2007-05-16
EP1839657A2 (en) 2007-10-03
WO1996015782A1 (en) 1996-05-30
PT789567E (en) 2007-08-24

Similar Documents

Publication Publication Date Title
CA2205134A1 (en) A method for treating vascular headaches
CA2391808A1 (en) Method for treatment of symptoms of central nervous system disorders
CA2282654A1 (en) Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
EP2567705A3 (en) Methods of treating cognitive dysfunction by modulating brain energy metabolism
EP0751709A4 (en) Methods of using bcl-2 for the therapeutic treatment and prevention of diseases
CA2186844A1 (en) Use of serotonin antagonists (5ht3) for treating fibromyalgia
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
NZ330061A (en) Process for recovering growth factors from milk or a milk derivative by separating out an growth factor enriched fraction and then further treating this fraction
AU1581295A (en) Unit for treating water by ozonation, and corresponding ozonised water production apparatus
CA2213339A1 (en) Method of treating adenosine depletion
ZA966240B (en) Methods for treatment of allergic asthma.
ATE188460T1 (en) METHOD FOR PRODUCING DERIVATIVES OF 4A,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPINE
EP0651650A4 (en) METHOD OF TREATING OPHTHALMIC DISORDERS USING TGF--g(b).
EP0820467A4 (en) Methods of treating disorders of the eye
CA2245768A1 (en) Methods for treating emesis and central nervous system disorders using optically pure (+) norcisapride
HU9502585D0 (en) Use of riluzole for treating aids-related neural disorders
WO1997009976A3 (en) Method of reducing neurotoxic injury with zinc chelators
WO2000021513A3 (en) Methods for treating multiple sclerosis
CA2180846A1 (en) Method of treating disorders of the eye
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
NO944340L (en) Melatonin derivatives for use in the treatment of desynchronization states
GB9402976D0 (en) Process for the treatment of contaminated land
BG102780A (en) Nasal application of agents for the treatment of delayed emesis fits
ZA976854B (en) Treatment of psychotic disorders.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed